NEW

Top 25 Biotech Companies of 2024

Article originally published on GEN The biotechnology industry achieved many firsts this past year, from the first approved drug that can slow the rates of cognitive and functional decline in adults with Alzheimer’s disease, to the first CRISPR-based gene editing...
White Paper

Navigating the European Union’s (EU) Drug Device Combination Product Regulatory Changes

process validation for expedited approval drugs

The European therapeutics market has been working to manage the upheaval caused by Brexit and is now working its way through yet another challenge: the medical devices regulation (MDR) changes that will soon go into effect and have significant impact on the regulation of combination products.

Regulation (EU) 2017/745 was enacted into law on May 25, 2017, replacing the EU’s Medical Device Directive (93/42EEC) and the EU’s Directive on active implantable medical devices (90/385/EEC). Per Article 117 of the new regulation, medicinal products with an integral medical device are subject to new requirements. Although a transition period was established, manufacturers and developers submitting drug–device combination (DDC) products for market approval on or after May 26, 2020, must comply with the new regulations.

With this deadline looming less than a year from now, what do these new regulations mean for combination drug manufacturers?

Download the Whitepaper

Previous

Next